Traditional Chinese Medicine Department
High-Throughput Drug Screening Platform
High-Content Screening (HSC) - Based High-Throughput Drug Screening Platform
Multiple monoclonal stable cell lines expressing green fluorescent protein have been constructed, and high-resolution microscopes are used to capture cell images. Combined with automated feature extraction and analysis, a high-content drug screening platform has been established, capable of conducting large-scale drug screening. By comparing changes in cell count, morphology, subcellular structures, and fluorescence signal changes over time before and after drug administration, the platform assesses the effects of drugs on various aspects of cells, including morphology, growth, differentiation, migration, apoptosis, metabolism, and signal transduction, in order to screen candidate drugs.
In vitro Experiment-Based High-Throughput Drug Screening Platform
Targeting key steps in the process of melanin production, a high-throughput drug screening platform has been established, forming a research and development path for the development of efficient whitening products based on enzyme inhibition and antioxidant activity. For common pathogenic microorganisms, a high-throughput drug screening platform for inhibiting bacterial or fungal growth has been constructed, providing candidate drugs for the treatment of infectious diseases.
Innovative Formula Development Platform
Innovative Formula Heihuang Chizhu Yin for Treating Chronic Heart Failure
By summarizing the pathological mechanism of chronic heart failure and understanding the pathogenesis from the perspective of TCM, the treatment principle of warming yang and supplementing qi, activating blood and eliminating stasis, resolving phlegm and promoting diuresis is identified as the guidance for the formula development. Formulae that reverse dysregulated signaling pathways of chronic heart failure are calculated based on targeted transcriptome and pathway enrichment analysis. Heihuang Chizhu Yin (HCY) is selected for anti-chronic heart failure based on expert experience with modification of the calculated formula. HCY can reverse more than 90% of the dysregulated pathways of chronic heart failure patients. The research aims to provide a new approach for the research and development of innovative Chinese herbal medicine. Using the combined analysis of single-cell transcriptomics and spatial transcriptomics, the mechanism of HCY in treating chronic heart failure is deeply analyzed. Supported by the Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine, the research institute is collaborating with multiple hospitals, including the Guang'anmen Hospital of China Academy of Chinese Medical Sciences, to conduct multicenter, randomized, controlled, double-blind clinical trials on HCY. In cooperation with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, general toxicology tests, safety pharmacology tests, and genetic toxicity tests have been performed for HCY.
Innovative Formula for COVID-19: Qiaobang Zhupi Yin
Based on targeted transcriptome, expert experience and artificial intelligence, the innovative formula Qiaobang Zhupi Yin (QBZPY) has been developed for the treatment of nonsevere coronavirus disease 2019 (COVID-19), along with the innovative formula Jubang-Huashi Yin (JBHSY) for the prevention of COVID-19. Both formulae are in line with TCM's treatment principles for COVID-19 and are capable of reversing the dysregulated signaling pathways in COVID-19 patients. Among them, QBZPY can reverse all COVID-19-related dysregulated signaling pathways in macrophages and lung epithelial cells, with a reversal rate of 100%. The monarch herbs in the QBZPY, including Lianqiao (Fructus Forsythiae), Xixiancao (Herba Siegesbeckiae) and Niubangzi (Fructus Arctii), can downregulate multiple signaling pathways related to virus infection, immune response, and epithelial damage.
The above-mentioned innovative formulae are currently translated into products by Beijing CapitalBio Pharma Co., Ltd.